RecruitMe Clinical Trial

A Phase 1/2a Pilot Study of Intravesical TSD-001 for Treatment of Low-Grade, Stage Ta, Non-Muscle Invasive Bladder Cancer
Study of New Treatment for Non-Muscle-Invasive Bladder Cancer
Sponsor:TesoRx Pharma
Enrolling:Male and Female Patients
Age Range:Between 18 and 85 years old
IRB Number:AAAR2604
U.S. Government ID:NCT03081858
Contact: Joel Decastro MD: 212-305-0114 / gjd16@cumc.columbia.edu
Additional Study Information:

The purpose of this study is to look at a new treatment for non-muscle-invasive bladder cancer. This new form of paclitaxel, a drug currently used by injection into a vein to treat various types of cancer, is designed to be instilled (injected) into the urinary bladder with a catheter (tube) placed into your bladder through your urethra (the opening where your urine comes out), which is about a five-minute office procedure. The catheter is then removed and you are observed in the office for 2 hours. This is an investigational product, which means that it is not approved for bladder injection by the Food and Drug Administration (FDA).

This study is closed
Investigator
Joel DeCastro, MD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Joel Decastro MD
Email: gjd16@cumc.columbia.edu
Phone: 212-305-0114